IGF-1 DES Dosing & Reconstitution Guide

IGF-1 DES can be administered via subcutaneous (SC) or intramuscular (IM) routes, with research studies indicating a frequency of administration typically set at once daily. The dose range reported in various studies spans from 20 to 100 micrograms per day, with specific dosages often tailored to the experimental context and objectives of the research. It is important to note that while these doses are derived from preclinical models, variability in individual response and experimental design may necessitate adjustments. Researchers should consider the pharmacokinetics of IGF-1 DES, which may influence the timing and frequency of dosing. Additionally, maintaining clarity in measurement units during preparation and administration is crucial to minimize dosing errors and ensure consistency across experiments.

Currently, there is no human safety data available for IGF-1 DES, which underscores the necessity for caution in its use. Theoretical risks include hypoglycemia, as activation of IGF-1 receptors can lead to decreased blood glucose levels. Furthermore, compared to native IGF-1, IGF-1 DES may pose an increased risk of uncontrolled cell proliferation due to diminished regulation by insulin-like growth factor-binding proteins (IGFBPs). This potential for enhanced growth signaling makes it particularly important to avoid use in individuals with active cancer or a history of cancer. Additionally, individuals with diabetes or those at risk for hypoglycemia should exercise extreme caution. Given the lack of safety data, IGF-1 DES is also contraindicated during pregnancy and breastfeeding, as the effects on fetal development and nursing infants remain unknown.